FLT4 (VEGFR3), Polyclonal Antibody

Rabbit anti Human FLT4 (VEGFR3) Polyclonal purified; FLT4; FLT; FLT-4; VEGFR3; polyclonal; PAb

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

Serum IgG fraction was purified by Protein A affinity chromatography.

0.2 um filtered solution in PBS with 5% trehalose.

The lyophilized antibody is stable for at least 1 year from date of receipt at -20 degree C.
Upon reconstitution, this antibody can be stored in working aliquots at 2 degree - 8 degree C for one month, or at -20 degree C for six months without detectable loss of activity.

Avoid repeated freeze/thaw cycles.
Shelf Life: >12 months

Small volumes of anti-FLT4 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

THE FLT4 receptor belongs to a family of protein tyrosine kinases that mediates signal transduction after engagement of their cognate ligands through a cascade of phosphorylation events. Along with FLT1 and FLK1 (or KDR), the two vascular endothelial growth factor (VEGF) receptors, FLT4 is a member of a subfamily of class III receptor tyrosine kinases characterized by seven extracellular Ig-like domains and a split, intracellular domain containing kinase activity. Tissue expression of the FLT4 receptor is relatively restricted, being found predominantly in lymphatic and microvascular endothelium.

Polyclonal

ELISA (EIA)

ELISA: Use at a concentration range of 0.5-1ug/ml. The detection limit for VEGFR3 is approximately 0.625 ng/well.

152,757 Da

Vascular endothelial growth factor receptor 3

VEGFR3; VEGFR-3; FLT-4  [Similar Products]

VGFR3_HUMAN

This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA. [provided by RefSeq, Jul 2008]

VEGFR3: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in ***** lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3- kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr- 185', and of AKT1 at 'Ser-473'. Interacts with VEGFC and VEGFD. Monomer in the absence of bound VEGFC or VEGFD. Homodimer in the presence of bound VEGFC or VEGFD. Can also form a heterodimer with KDR. Interacts with PTPN14; the interaction is enhanced by stimulation with VEGFC. Interacts with CRK, GRB2, PTK2/FAK1, SHC1, PIK3R1 and PTPN11/SHP- 2. Identified in a complex with SRC and ITGB1. Detected in endothelial cells. Widely expressed. Detected in fetal spleen, lung and brain. Detected in ***** liver, muscle, thymus, placenta, lung, testis, ovary, prostate, heart, and kidney. Present in an inactive conformation in the absence of bound ligand. Binding of VEGFC or VEGFD leads to dimerization and activation by autophosphorylation on tyrosine residues. Inhibited by MAZ51. Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Protein kinase, TK; Protein kinase, tyrosine (receptor); EC 2.7.10.1; Membrane protein, integral; Kinase, protein; TK group; VEGFR family

Chromosomal Location of Human Ortholog: 5q35.3

Cellular Component: integral to plasma membrane; cytoplasm; extracellular region; plasma membrane; nucleus; receptor complex

Molecular Function: vascular endothelial growth factor receptor activity; protein binding; growth factor binding; transmembrane receptor protein tyrosine kinase activity; protein phosphatase binding; ATP binding

Biological Process: peptidyl-tyrosine phosphorylation; protein amino acid autophosphorylation; positive regulation of JNK cascade; vasculature development; positive regulation of MAPKKK cascade; lymphangiogenesis; positive regulation of cell proliferation; blood vessel morphogenesis; positive regulation of endothelial cell proliferation; positive regulation of protein amino acid phosphorylation; sprouting angiogenesis; vascular endothelial growth factor receptor signaling pathway; lymph vessel development; transmembrane receptor protein tyrosine kinase signaling pathway; negative regulation of apoptosis

Disease: Hemangioma, Capillary Infantile; Lymphedema, Hereditary, Ia

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.